Ramy Sedhom, MD, FASCO

Imagine 4 new anticancer drugs Pallituzumab, Geriatriximab, Symptomab, & Exercizumab hit the market. They should dominate the plenary sessions at ASCO & command billion-dollar revenue. But they don't because they're nonpharmacologic & shame on us. Read our opinion piece in @JCO_ASCO ascopubs.org/doi/full/10.12…

@fedelosco @DrChoueiri @EgyptNT @FIFAWorldCup @minasedrakmd @Noha_Soror That was a big scare yesterday! Amazing game - I’d love for Messi to win another

@DrChoueiri @EgyptNT @FIFAWorldCup @minasedrakmd @Noha_Soror @ramsedhom 🇦🇷 is coming

History made: @EgyptNT 🇪🇬 beats @FootballAUSp 🇦🇺 @FIFAWorldCup 2026!

There’s More to the Mental Health Crisis Than Smartphones and Social Media open.substack.com/pub/adamgrant/…

Mo Salah dancing on the streets of Vancouver with fans, after he scores to help Egypt win their first ever World Cup game.🇪🇬🕺🏻

We are optimizing treatment for young onset CRC but 41% are walking in emotionally distressed & only 27% get the support they need. The tumor is not the only target. Nice report on how dedicated navigation services improve supportive care access ascopubs.org/doi/abs/10.120…

Almost game time. Retweet for #KnicksIn5!

A 20-point deficit means NOTHING to the Knicks 😤

Cast of Laocoön and his Sons (Roman version of a lost Greek original), 100BC-50AD

KNICKS!

I'm excited to host @OncLive State of the Science Summit in Philadelphia - with a focus on Breast Cancer. We have put together an excellent faculty & would love to have you join us if you are in the area - registration.onclive.com/state-of-the-s…

@Dr_RShatsky @BianchiniGP There have been other study in the past in bone mets with different tumors. Same results. We use 3m periodicity since a long time.

Wow, #Asco26 discussant Julie Brahmer is distinctly restrained (OK, scathing!) in her enthusiasm for Harmoni-6 $SMMT

What I appreciate most about this trial is the # of older adults enrolled >50% above age 65 @EileenMOReilly

@NarjustFlorezMD @OncoAlert @OncogeneCancer @YoungLungCancer @ASCO @ASCOPres @IASLC @SMMT_TX @women_in_cancer @OncBrothers Also bizarre there is an age cutoff of 75 for a disease with a median age at diagnosis in the 70s

@PTarantinoMD @ASCO It’s based off learning theory & we even see in journalism (“don’t bury the lead”) Ultimately helps with cognitive bandwidth and helps with framing while listening

@ASCO please Let’s go back to including the trial conclusions only at the END of the presentations!

#ASCO26: Using the Collaborative Care Model to address #mentalhealth care disparities in community #oncology clinics showed meaningful decreases in depressive symptoms. Ft. PC3I Program Director @ramsedhom @ASCO #ASCO asco.org/abstracts-pres…

Deep inner suffering inevitably arises when the human person is reduced to performance, consumption, or a statistical datum. Many young people today live under the yoke of expectations to perform, immersed in an exasperated competitiveness that generates anxiety, fear of not measuring up, and disorientation.

A really thought-provoking study at #ASCO26 (Abstr 4512, Clinical Science Symposium): decision regret after adjuvant pembrolizumab in RCC. 🔹 The question Do patients regret receiving adjuvant pembro — and if so, is it driven by long-term toxicity that CTCAE grading doesn't adequately reflect? They built a patient co-designed tool focused on long-term toxicity. 🔹 The study 104 RCC pts post-adjuvant pembro across 3 London centres, median f/u 30 mo. Pts completed the Ottawa Decision Regret Scale alongside their own rating of irAEs as life-changing, significant, or non-significant. 🔹 What they found 28% rated their toxicity as significant and 11% as life-changing — but these ratings did NOT correlate with CTCAE grade (a third of G1–2 events were rated significant), and regret was identical for G1–2 vs G3–4 irAEs. Regret was driven by patient-perceived long-term toxicity, especially permanent endocrine and MSK irAEs — and not by disease recurrence (only 1/14 who relapsed expressed regret). Lower baseline expectations of toxicity → more regret. 🔹 My take Striking that >1 in 4 reported significant and >1 in 10 life-changing toxicity. What concerns me most isn't that CTCAE missed these events — it's that the grade didn't correlate with how significant patients found them, nor with regret at all. That deviates from the very purpose of grading. The hard part: a regret analysis is tough to contextualize when the alternative, no treatment, risks recurrence — arguably worse than a long-term toxicity. Adjuvant therapy is challenging by nature: most patients are either cured already or destined to recur regardless — we expose everyone to toxicity to benefit a minority. We urgently need biomarkers to find the few who truly benefit. This slide from @Prof_IanD says it all 👇 Looking forward to seeing the presentation! 🔗 asco.org/abstracts-pres… #kcsm #ASCO26 @BethN01 @tompowles1